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Measuring the ability of agonist compounds 
to induce a cellular response (embodied in 
the pharmacological parameter known as 
efficacy)1 is a key part of the drug discovery 
process. Historically, it was thought that ago-
nists acting at a given seven-transmembrane 
receptor — also known as a G-protein coupled 
receptor (GPCR) — could have different 
efficacies but each agonist would activate 
a similar set of signalling proteins. This is 
because it was thought that all agonists acti-
vate receptors by stabilizing a single active 
conformation of the receptor (known as the 
active state) and that it was only the strength 
of the imparted signal that determined the 
magnitude of the observed efficacy.
A product of this model is the agonist 
‘potency ratio’: that is, the ratio of agonist 
concentrations that produce 50% of the max-
imal response in an in vitro assay. Agonist 
potency ratios are mathematical expressions 
of relative agonist activity that are depend-
ent only on the drug-related parameters of 
affinity and efficacy. Therefore, they are null 
measurements that allow the quantification 
of the relative activity of agonists in one  
system (for example, in a test system) to  
predict their activity in all other systems  
(for example, therapeutic systems).
Agonist potency ratios have been highly 
valuable to the drug discovery process,  
as drugs are rarely — if ever — developed 
directly in the therapeutic system. In order 
for agonist potency ratios to correctly pre-
dict the relative agonist activity in a system 
other than the test system, the paramount 
assumption is that the link between the 
initial agonist stimulus at the receptor (x) 
and the cellular response (y) is monotonic; 
that is, there can be only one value of y for 
every value of x. When this assumption is 
not valid, agonist potency ratios that are 
determined in whole-cell systems become 
dependent on the test system (such as the 
particular cell line) and considerably less 
useful for drug discovery.
The subsequent recognition that there 
is substantial pleiotropy in the interaction 
between seven-transmembrane receptors 
and multiple cellular signalling proteins  
has led to an important concept in drug  
discovery: namely, that efficacy has a  
quality as well as a magnitude. This is  
due to the fact that many agonists do not  
activate receptors through stabilization  
of the same active state; rather, they stabi-
lize unique active states to create a signal 
that is ‘biased’ towards specific cellular  
pathways2 (FIG. 1) (reviewed in REFS 3–6). 
This phenomenon is revolutionizing  
seven-transmembrane receptor drug dis-
covery and may furnish drugs with more 
therapeutically useful profiles. For example, 
as discussed below, biased opioid receptor  
agonists that are devoid of respiratory 
depressive properties could be developed 
for analgesia7–10.
In general, as discussed below, biased 
agonists may have superior therapeutic 
profiles in many disease areas and indica-
tions, including the treatment of pain, heart 
failure, osteoporosis and metabolic diseases. 
However, the identification of biased ago-
nists also changes the way agonism must 
be quantified. In this article, we highlight 
examples of the biased activation of seven-
transmembrane receptors and how they may 
yield better therapeutic entities. We also 
highlight the pharmacological challenges to 
the drug discovery process resulting from 
this more complex mechanism of receptor 
function. Foremost among these challenges 
is the need to quantify agonist bias in a 
meaningful way to allow medicinal chemists 
to optimize biased activity; here, we present 
a comparison of the currently proposed 
methods to do this as well as the evidence 
that, in our opinion, indicates the most 
robust and useful approaches. Finally, we 
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Abstract | Agonists of seven-transmembrane receptors, also known as G protein- 
coupled receptors (GPCRs), do not uniformly activate all cellular signalling 
pathways linked to a given seven-transmembrane receptor (a phenomenon termed 
ligand or agonist bias); this discovery has changed how high-throughput screens 
are designed and how lead compounds are optimized for therapeutic activity. 
The ability to experimentally detect ligand bias has necessitated the development 
of methods for quantifying agonist bias in a way that can be used to guide 
structure–activity studies and the selection of drug candidates. Here, we provide 
a viewpoint on which methods are appropriate for quantifying bias, based 
on knowledge of how cellular and intracellular signalling proteins control the 
conformation of seven-transmembrane receptors. We also discuss possible 
predictions of how biased molecules may perform in vivo, and what potential 
therapeutic advantages they may provide.
Figure 1 | Trafficking of receptor stimulus by agonists. a | Biased agonism: agonist A produces 
a biased stimulus for cellular signalling pathway 1, whereas agonist B produces another receptor 
conformation that selectively induces bias for cellular signalling pathway 2. b | Biased modulation: 
an allosteric ligand binds to the receptor, causing a change in the bias of the endogenous agonist.
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consider challenges beyond the in vitro char-
acterization of biased signalling by considering 
the prediction of biased agonism in vivo.
Measuring agonism in drug discovery
The concentration–response curve is a time-
honoured way of determining the activity 
of a compound. This tool conveys potency 
(as a position along the concentration axis) 
and maximal activity (related to efficacy 
as the maximal response). These curves 
can readily be determined in vitro for any 
defined pharmacological response, such as 
the production of a receptor-mediated sec-
ond messenger (for example, cyclic AMP or 
calcium) or the interaction of the receptor 
with signalling proteins such as β-arrestin 
or G proteins. Through concentration–
response curves, the relative activity of ago-
nists on different signalling pathways can be 
compared and biased agonism determined. 
For a possible bias to be identified at the 
compound screening stage, it is necessary to 
separately determine a full concentration–
response curve (not single-point measures of 
response) for each signalling pathway so that 
the pathways can be differentiated. Although 
this constitutes an early commitment to 
quantitative analysis during the screening 
process, the parameters derived from full 
concentration–response curves can be used 
to provide quantitative estimates of ligand 
bias that can be used for the taxonomy of 
possible candidate molecules during the 
development process.
As a preface to the discussion of the 
thera peutic ramifications of biased signal-
ling, it is useful to define what is meant 
by the term ‘bias’, as it is a product both of 
how agonist response is observed and how 
molecules interact with receptor proteins. 
It is important to distinguish between these 
effects as the in vitro agonist response is an 
experimental artefact that is unique to the 
systems being studied, whereas only the 
interaction with receptor proteins is a molec-
ular property of the biased agonist that can 
be exploited therapeutically in all systems.
Interpretation of the term ‘bias’
Agonist bias was first described in theoretical 
terms as ‘stimulus trafficking’, referring to the 
stabilization of unique conformations of  
the active state of the receptor2, although there 
were previous reports in the literature11–17  
of data that were incompatible with models of 
a single active state of seven-transmembrane 
receptors. Since its identification, the phenom-
enon has been given many names, including 
stimulus trafficking2, agonist-directed traf-
ficking of a receptor stimulus18, functional 
dissociation19, biased agonism20, asym-
metrical signalling20, biased inhibition21, 
differential engagement22, discrete activation 
of transduction16, stimulus bias and functional 
selectivity23–26. The most commonly used 
terms used to describe this effect are: biased 
agonism, biased signalling, stimulus bias and 
functional selectivity.
In general terms, agonist bias can be  
visualized if two cellular responses (A and B)  
to a defined agonist are plotted as functions 
of each other: that is, the amount of signal 
produced in pathway B is plotted as a func-
tion of equal amounts of signal produced in 
pathway A in response to equimolar con-
centrations of a given agonist. This results 
in a ‘bias plot’5,26, a theoretical example of 
which is shown in FIG. 2. Unless this function 
is a straight line, the bias plot will indicate 
that the agonist produces a relatively higher 
response to one of the pathways compared 
with the other. Bias plots are useful for 
graphically expressing the differential  
activation of two cellular pathways by the 
same agonist. However, it must be noted  
that bias plots reflect three different types  
of agonist-induced changes in cellular  
signalling (see below), only one of which  
can be therapeutically targeted.
System bias. System bias reflects the relative 
efficiency with which different pathways 
may be coupled to signalling proteins in the 
cell. Differences in these efficiencies stem 
from the relative sensitivity of cellular path-
ways. For example, in rat atria the concentra-
tions of cAMP needed to induce myocardial 
relaxation are lower than the concentrations 
needed to induce positive inotropy27.  
System bias will be common for all agonists 
acting on any specific receptor so it cannot 
be exploited for therapeutic advantage.
Figure 2 | Bias plots. Responses to four agonists (numbered agonist 1 to 4) in two assay systems 
(assay A (part a) and assay B (part b)) are shown. Concentration–response curves in parts a and b show 
the responses to the agonists in each assay. The bias plot (part c) shows the response in assay A as a 
function of the corresponding response in assay B for the four agonists. Agonist 1 is chosen as the 
reference agonist (any of the four agonists can be used as the reference agonist). It can be seen that 
agonist 2 produces comparable responses in assay A (as a function of responses in assay B) to agonist 1. 
The fact that the lines are curved indicates the degree of system and observational bias in the 
systems. Agonist 3 produces a considerably lower response in assay A as a function of its responses 
in assay B, indicating a bias towards response B. Agonist 4 produces considerably greater responses in 
assay A for defined responses in assay B, indicating a bias towards response A.
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Observational bias. Another type of bias 
that is observed when measuring agonism 
in two different assays is caused by the 
sensitivity of the various assays that are 
used to visualize the response of the cell to 
agonist stimulation; in this article we refer 
to this as ‘observational bias’. Here, the rela-
tive sensitivity of each assay determines the 
relative potency of agonists in those assays, 
and this fact precludes a direct comparison 
of these pathways as a measure of bias. For 
example, the β-adrenergic receptor agonist 
isoprenaline has an approximately 500-fold 
difference in potency for cAMP production 
relative to extracellular signal-regulated 
kinase 1 (ERK1) or ERK2 phosphorylation 
in the same cell type28.
Observational bias is a function of the 
experimental conditions (for example, buffers, 
reagents, temperatures as well as temporal 
and/or kinetic considerations) that are unique 
to the assays being used to visualize pathway 
responses and, as with system bias, all agonists 
will be subject to this effect. As it is an arbi-
trary product of the sensitivities of the assays 
used to quantify agonism, it has no bearing 
on therapeutically useful signalling bias.
Agonist bias. If comparing the effects of a 
set of agonists on different cellular pathways 
reveals differences in the activation of signal-
ling pathways that are not due to observa-
tional or system bias, they can be caused by 
ligand bias. Because different intracellular 
signalling pathways have various sensitivities 
to agonists, ligand bias must be detected and 
quantified by comparing the activity of ago-
nists within one assay to a selected standard 
agonist (in order to remove observational 
bias and system bias). The relative activity of 
each agonist in one assay can then be com-
pared to its relative activity in other assays 
(compared to the same reference agonist in 
each assay) to yield a relative activity ratio 
that corrects for system bias and observa-
tional bias and can be used across assays to 
detect true ligand bias between signalling 
pathways (see the next section).
Biased agonism is associated with the 
molecular structure of the agonist and 
so it can be exploited therapeutically. 
Pharmacological studies using agonists in cell 
systems provided the initial data supporting 
the notion that not all agonists stabilize the 
same active state of a seven-transmembrane 
receptor to produce a cellular response. This 
idea has been confirmed through a range of 
biochemical studies using fluorescence spec-
troscopy29–36, plasmon waveguide resonance 
spectroscopy37,38, bioluminescence resonance 
energy transfer35,39, circular dichroism40, 
X-ray crystallography41, site-directed 
mutagenesis and molecular modelling42 
as well as 19F-NMR spectroscopy43. Biased 
signalling is observed with many ligands 
that have also been shown to biochemically 
stabilize different seven-transmembrane 
receptor conformations3–6; this has led to an 
association between heterogeneous recep-
tor conformations and the phenomenon of 
biased signalling.
Bias in signalling is caused by the inter-
action of unique conformations of the active 
state of the receptor with signalling proteins 
to produce different relative levels of stimu-
lation to downstream pathways. It can be 
induced directly by the binding of agonists 
to the receptor (FIG. 1a) or it can be caused 
indirectly by the binding of modulators that 
induce biased signalling via the endogenous 
agonist (FIG. 1b).
The term ‘biased’ is a conditional term 
and must always be used in the context of 
another ligand (for example, ligand x is 
biased towards β-arrestin signalling in com-
parison with ligand y). A standard ligand 
must be used in assays to detect biased 
agonism; although the endogenous agonist 
ligand would be an obvious choice, it must 
be remembered that endogenous agonists 
will also exhibit bias because of the exist-
ence of system bias. Thus, a synthetic agonist 
would be biased with respect to the endog-
enous ligand, but that does not mean the 
endogenous ligand is unbiased.
There are examples where a given agonist 
activates one pathway but fails to induce a 
response in an assay for another pathway; 
this has been referred to as ‘perfect bias’. 
Caution must be exercised in the use of such 
a label, as it implies that the agonist does not 
Figure 3 | Chemokine activation of CCR5. a | Chemokine-mediated activation of chemokine CC 
motif receptor (CCR5) by different agonists in U373 cells results in increased inositol-1-phosphate 
(Ins-1-P) production, and the transduction ratios (log(τ/K
A
) values) can be determined. The values in 
the box below the figure refer to log transduction ratios (log(τ/K
A
). b | Chemokine-mediated inter-
nalization of CCR5 by different agonists in U373 cells; the values in the box below the figure refer to 
transduction ratios for this process. The respective transduction ratios, expressed as ratios of the 
value for a reference agonist (in this case, chemokine CC ligand 3 (CCL3)), are shown in the box below 
the figures. c | Ratios of these numbers are used to calculate the relative bias of the agonists for the 
two processes. In this case, CCL3L1 is 32.4 times more active than CCL3 at inducing CCR5 inter-
nalization when activating CCR5. Data modified, with permission, from REF. 45 © (2012) American 
Chemical Society.
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activate the pathway in all tissues. It cannot 
be assumed that in vitro experimental con-
ditions will mimic the pathological condi-
tions that determine the effects of a drug 
when it is administered therapeutically. 
When apparent ‘perfect bias’ is encountered, 
it may be due to the fact that the assay for 
that pathway is not sensitive enough to 
detect the effect of the agonist. The use of a 
more sensitive assay for this pathway might 
reveal that the agonist can produce a surpris-
ingly powerful effect.
Quantifying bias: survey of methods
It is optimal to characterize and quantify 
agonist activity in any system in terms of  
a single parameter, as this will allow the 
application of statistical methods to assess 
true differences in agonist activity between 
drugs. Using potency (pEC50 values) to 
characterize and quantify agonist activity is 
inadequate for agonists that produce differ-
ent maximal responses. Conversely, using 
only maximal response to characterize and 
quantify agonist activity fails to differentiate 
between full agonists, which produce a stimu-
lus that exceeds the signalling capabilities of 
the system (thus all agonists yield a uniform 
maximal response). Therefore, a scale that 
includes elements of both potency and maxi-
mal response is required. Some methods 
have been described to quantify bias and it is 
thus timely to compare the various methods 
available.
Transduction coefficients. As a preface to 
a discussion of methods used to quantify 
biased agonism, it is useful to examine the 
theoretical framework for assessing agonism, 
and a valuable model in this regard is the 
Black–Leff operational model44 for quanti-
fying drug responses (see Supplementary 
information S1 (box)). Within this model, 
agonism can be quantified in a system-
independent parameter that considers both 
the operational affinity and efficacy of agonists 
in the form of a ‘transduction coefficient’:  
τ/KA
45; the term τ incorporates agonist effi-
cacy, receptor density and coupling within 
the system, and the dissociation constant KA 
is the reciprocal of the conditional affinity of 
the agonist in the functional system.
For full agonists, a given potency can 
result from infinite combinations of effica-
cies and affinities. Ratios of τ/KA values are 
identifiable as a unique value associated 
with a given agonist potency as they are 
essentially the reciprocal of the EC50 value 
produced by a full agonist (that is, a single 
value). It has been shown experimentally that 
transduction coefficients remain constant 
over large changes in receptor density45; this 
is a required property for a scale that is used 
to determine agonist bias, as it would be 
expected that different tissues would have 
varying receptor densities on the cell surface.
It should be noted that the KA parameter 
in this calculation is a measure of the con-
ditional affinity and not the affinity of the 
ligand for the bare receptor (that is, the recep-
tor uncoupled from intracellular signalling 
proteins). As the receptor functions by cou-
pling to signalling proteins, the affinity of the 
agonist for the bare receptor is not relevant to 
the functional activity of the ligand in a cell-
ular system (the bare receptor produces no 
functional response). In the scheme shown 
below, the agonist A thus promotes a change 
in the receptor from the R to the R* state:
Nature Reviews | Drug Discovery
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φ
The receptor ‘isomerizes’ (that is, it 
becomes another thermodynamic protein 
species through ligand binding) from the R 
Box 1 | Differences in bias calculated with log transduction ratios versus σlig values
One method proposed to quantify bias is through σ
lig 
values: namely, the ratios of the efficacy of 
agonists for the activation of a given signalling pathway in a cell. This method assumes that the 
affinity values for the agonist–receptor complex in the activation of separate signalling pathways 
are identical61. If this assumption is incorrect, this method could lead to substantial errors in the 
estimation of bias; the magnitude of these errors can be calculated. Thus, as defined in REF. 61 for 
two agonists designated ‘lig’ and ‘ref’:
Here, τ
lig
 and τ
ref
 refer to the efficacies of the test and reference agonists, respectively, in the 
activation of a signalling pathway.
Different signalling pathways are then compared and the difference quantified in the term β
lig
:
Here, the pathways are denoted ‘path 1’ and ‘path 2’.
An equation can be derived (see Supplementary information S7 (box) for the derivation) to 
demonstrate the relationship between β
lig
 and ΔΔlog(τ/K
A
)45 values as estimates of bias:
Here, K
A‑lig
 and K
A‑ref
 are the K
A
 values for the test and reference agonists, respectively.  
The second and third terms on the right side of the equation refer to any possible differences in 
the affinity of the agonists when they bind to the seven‑transmembrane receptor (also known as  
G protein‑coupled receptor) and subsequently bind to signalling proteins in pathways 1 and 2.  
If the affinity of both agonists is identical when pathways 1 and 2 are activated, then these 
terms will approach zero:
If, however, there is an allosterically mediated difference in the functional affinity of either the 
test or reference agonist as the receptor interacts with the two pathways, then there will be a 
difference between the estimates made with ratios of transduction coefficients and those made 
with the β
lig
, with a magnitude equal to that shown in Supplementary information S7 (box):
Although there are theoretical reasons why the use of assumed uniform affinity values may lead  
to erroneous estimates of bias, and there are examples of situations where a single affinity 
value cannot be used to fit the operational model to give ΔΔlog(τ/K
A
) or σ
lig
 values48–50, there  
are cases in the literature where σ
lig
 values have been reported and do give a value for bias61.  
The relative effect of signalling proteins on receptor affinity versus efficacy (the type of 
receptor active state formed) for agonism (see Supplementary information S7 (box)) 
dictates whether there will be an error in these bias estimates. In situations where this is  
the case, equation 5 from Supplementary information S7 (box) indicates the size of the error. 
However, it should also be noted that there are instances where a single binding affinity 
appears to model the functional affinity of agonists, and in these cases the β
lig
 values will give  
an accurate estimate of bias. 
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= (3)σlig
τlig
τref
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= (4)βlig
σligpath1 – σligpath2
√2
Nature Reviews | Drug Discovery
= (5)βlig ∆∆log(τ/KA)lig-ref (log(KA-ref/KA-lig))path2+ (log(KA-ref)KA-lig))path1–√2
Nature Reviews | Drug Discovery
= (6)βlig ∆∆log(τ/KA)lig-ref√2
Nature Reviews | Drug Discovery
∆log bias  =  log +  log
KA-refpath2
KA-refpath1
(7)
KA-ligpath1
KA-ligpath2
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to the R* state through the efficacy-related 
processes γ and ϕ (that is, the conforma-
tional state of the receptor is not confined  
to the agonist–receptor (AR) complex)46,47. 
The observed affinity will be an amalgam 
value, KA, of the magnitude:
Nature Reviews | Drug Discovery
KA =
1 +
K
(2)γ
φ
The application of the Black–Leff opera-
tional model to agonism has been described 
in the literature48–50 to show the differences in  
the functional affinity of agonists when 
they activate separate signalling pathways; 
specifically, the operational model can-
not accommodate data for partial agonists 
with divergent EC50 values by using a single 
KA value. These data underscore the find-
ing that there are examples showing that a 
single estimate of affinity fails to adequately 
describe the functional agonist activation of 
multiple signalling pathways. These examples 
are described in Supplementary information 
S2 (box).
Seven-transmembrane receptor agonism 
is an allosteric process defined by the facili-
tation of receptor–protein interactions with 
signalling proteins (such as G proteins and 
β-arrestin) following the binding of agonist 
molecules. This means that the affinity  
of ligands for seven-transmembrane 
receptors may depend on the interaction 
of that receptor protein with other signal-
ling proteins in the cell. Thus, as in all 
allosteric systems, the affinity of the ago-
nist is conditional on the properties and 
concentration of the signalling protein. The 
agonist–receptor–transducer complex, and 
not just the agonist–receptor complex, is 
therefore the minimal biological unit needed 
to produce a cellular response51. This idea 
is supported by structural studies of the 
β2-adrenergic receptor showing changes in 
the three-dimensional structure of the recep-
tor with either a G protein52 or a nanobody 
that mimics G protein binding53; such struc-
tural changes would suggest a concomitant 
alteration in agonist affinity (Supplementary 
information S3 (box)).
In general, it is our view that the KA value 
in the operational model should not be 
confused with independently determined 
KA values from binding assays as they are 
intrinsically different. The idea that agonist 
affinity may be conditional and subject to 
the nature of the signalling protein that is 
associated with different signalling pathways 
argues against the use of a single biochemi-
cal estimate of agonist affinity derived from 
a single binding study for use in the calcula-
tion of bias (as discussed below).
The transduction coefficient scale 
reduces the measurement of agonism to 
a single number and thus enables the sta-
tistical analysis of differences. The key for 
the correct use of this scale is as follows: 
first, compare values for a set of agonists to 
each other within a given pathway; second, 
express log(τ/KA) ratios (the relative power 
of each agonist to induce a response) as 
ratios to a defined reference agonist (that is, 
as Δlog(τ/KA)) as this will cancel the effects 
of system and observational bias. Finally, 
relative activity ratios of each agonist across 
different pathways (as ΔΔlog(τ/KA) values) 
can be determined as measures of agonist 
bias. An example of this procedure is shown 
in FIG. 3.
Relative activity values. Another parameter 
that has been used to quantify biased ago-
nism is the ‘relative activity’ scale54–56. This 
scale uses a ratio of the maximal response 
to the EC50 value for an agonist (log (relative 
activity; RA) = log(max/EC50)); this takes 
into account the agonist potency and the 
maximal response produced by an agonist in 
a given system. For concentration–response 
curves with slopes that are not significantly 
different from unity, it can be shown that the 
relative activity value reduces to transduc-
tion coefficient values57. The log(RA) scale 
has the advantage of being simple to cal-
culate in cases where fitting the data to the 
Black–Leff operational model is problematic 
(see Supplementary information S4 (box)), 
but it requires that the slope of the concen-
tration–response curves is not significantly 
different from unity. The comparison of 
log(RA) values thus offers another method 
of quantifying agonist bias58.
Comparison of agonist equiactive concentra-
tions. Another method used to quantify ago-
nism, which was originally used to estimate 
the relative affinity of a partial agonist59,60, 
compares equiactive concentrations of a full 
and partial agonist to calculate the ratios of 
agonist efficacy and agonist affinity for  
each agonist (τ/KA). When applied to a single 
signalling pathway, this furnishes ratios of 
transduction coefficients (Supplementary 
information S5 (box)). As with the relative 
activity scale, this method is only valid for 
functional systems in which the concentra-
tion–response curves have slopes that are 
not significantly different from unity.
βlig and σlig values. Another method that 
has been proposed to quantify agonist 
bias calculates a term designated as βlig
61. 
This method is similar to the transduction 
co efficient method as it uses the Black–Leff 
operational model to estimate the efficacy 
of the agonist (τ values). However, it differs 
from the transduction coefficient scale by 
assuming that a single estimate of KA for the 
receptor (obtained from biochemical bind-
ing studies) should be used to fit the data 
to the operational models. This therefore 
means that the dissociation constant (KA) 
will effectively be the same for each path-
way at which biased agonism is calculated. 
For the reasons highlighted above, there is 
Figure 4 | Logistical scheme for quantifying signalling bias for agonists in a system-independent 
manner. The scheme illustrated will be system-independent only for defined in vitro systems that 
measure a molecular allosteric vector (direct interaction between a ligand, receptor and signalling 
molecule). Bias estimates may become cell-type-dependent for biased agonists in whole-cell assays 
or assays in which other signalling components of the cell contribute to the observed response. 
K
A
, dissociation constant; pEC
50
, negative logarithm of the EC
50
; RA, relative activity.
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little rationale for assuming that the func-
tional affinity of an agonist for its recep-
tor will be the same when that receptor 
interacts with different cellular signalling 
proteins. If the affinity of the agonist does 
change when different signalling proteins 
are coupled to the receptor, the use of an 
independent single estimate of agonist 
affinity for the calculation of βlig values may 
introduce an error into the calculation of 
bias. The size of this error is dependent 
on the magnitude of the difference in the 
operational affinity of the agonist for the 
receptor, as the receptor interacts with dif-
ferent pathways (Supplementary informa-
tion S2 (box)), and can be unpredictable 
(see Supplementary information S6 (box) 
for further details).
This raises the possibility that the affinity 
of certain agonists may change only slightly 
in the presence of different guest signalling 
molecules on the receptor, making the error 
term for bias of these specific molecules rel-
atively small (see BOX 1 and Supplementary 
information S7 (box)). Depending on the 
differences in receptor affinity with vari-
ous signalling pathways, the σlig method 
will produce estimations of bias that are 
very similar to the transduction coefficient 
method for some agonists and very different 
for others.
Preferred methods to quantify ligand bias?
In general, we believe that the theoretically 
most sound method of quantifying ligand 
bias in vitro is through ratios of transduc-
tion coefficients (ΔΔlog(τ/KA)) or ratios 
of changes in relative activity (ΔΔlog(RA) 
values for agonists that produce concentra-
tion–response relationships with slopes that 
are not significantly different from unity), 
certainly in cases where it can be shown that 
the application of a uniform affinity value 
cannot mathematically fit the concentra-
tion–response curves for multiple pathways 
for some agonists (see Supplementary  
information S2 (box)). The use of σlig and  
βlig values will provide useful estimates of  
agonist bias in cases where the affinity  
of the receptor for the ligand has been 
shown to remain constant in different 
signalling pathways. In assays in which 
agonists have the same observed maximal 
response (that is, full agonists), the use of 
ΔpEC50 values to determine bias is sufficient. 
Agonist equiactive concentrations can  
also be used to compare full and partial  
agonists in order to yield ratios of transduc-
tion coefficients. A general scheme for  
comparing various types of agonists is  
given in FIG. 4.
Translating bias to in vivo effects
Methods such as those discussed above can 
be used to derive estimates of ligand bias 
factors for a defined set of in vitro experi-
mental conditions, but agonists will probably 
encounter a range of tissues with varying  
sensitivity to agonists and different receptor 
densities in vivo. It is expected that differ-
ences in receptor density, the relative stoichio-
metry of signalling elements and receptor 
coupling efficiencies will lead to quantitative 
differences in cellular signals for different 
agonists. For example, in Chinese hamster 
ovary (CHO) cells containing high levels 
of expression of β3-adrenergic receptors 
the dominant signalling pathway is cAMP, 
whereas at low levels of expression the signal-
ling pathway changes to mitogen-activated 
protein kinase 14 (MAPK14; also known 
as p38 MAPK); this change leads to sub-
stantial differences in the biased signalling 
of the ligands CL316243 ((R,R)-5-[2-[[2-
(3-chlorophenyl)-2-hydroxyethyl]-amino]-
propyl]1,3-benzodioxole-2,2-decarboxyl
ate) and SR59230A (3-(2-ethylphenoxy)-1-
[(1,S)-1,2,3,4-tetra hydronapth-1-ylamino]-
2S-2-propanol oxalate)62.
The impact of tissue sensitivity (or receptor  
density) on agonist bias is shown in FIG. 5. 
Specifically, in a highly sensitive tissue an 
agonist with a defined bias for pathway 1  
over pathway 2 (determined as a transduc-
tion coefficient defined by Δlog(τ/KA)(1–2)  
= 0.824) induces a greater response in path-
way 1 over a broad concentration range.  
By contrast, in a tissue with lower sensitivity  
to agonists, this same agonist (with the same 
ligand bias) induces a greater response in 
pathway 1 (over pathway 2) at low con-
centration ranges but a greater response 
in pathway 2 (over pathway 1) at higher 
concentration ranges.
The unpredictable bias of agonists in 
tissues of varying sensitivity highlights that 
the magnitude of agonist efficacy also has a 
role in the interaction between efficacy and 
affinity. That is, there can be two agonists 
Figure 5 | Interplay of tissue sensitivity and ligand bias. Panel a shows the concentration–response 
curves of the agonist for the two pathways in the sensitive tissue. Panel b shows the concentration–
response curves of the agonist for the two pathways in the tissue with low sensitivity. Panel c shows 
that an agonist with a defined bias for pathway 1 over pathway 2 (relative log(transduction ratio; 
Δlog(τ/K
A
)
(1-2)
 = 0.824) can show variable effective bias in vivo in tissues with differing receptor density. 
In this simulation, in a sensitive tissue with a high receptor density the agonist shows a clear bias 
throughout the full concentration range for the response, as indicated by the orange hyperbolic line 
on the left of the line of equivalence (dotted straight line). However, in a tissue of lower sensitivity 
(black hyperbolic line), the hyperbolic asymptotic value at ordinate = 0.45 shows that over a low con-
centration range the effect of the agonist is biased for pathway 1 over pathway 2, but at higher agonist 
concentrations this changes to a preference for pathway 2 over pathway 1. Parameters for agonist: 
high-sensitivity tissue: log(τ/K
A
)
1
 = 7.3; log(τ/K
A
)
2
 = 6.48; Δlog(τ/K
A
)
(1–2)
 = 0.824. Low-sensitivity tissue: 
log(τ/K
A
)
1
 = 5.0; log(τ/K
A
)
2
 = 4.18; Δlog(τ/K
A
 
(1–2)
) = 0.824. 7TMR, seven-transmembrane receptor.
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with an identical bias but differing strengths 
of efficacy, and these agonists may behave 
differently in vivo. These types of effects 
make the in vivo prediction of biased agonist 
profiles difficult.
At present, owing to the lack of methods 
that allow the stable prediction of biased 
agonism in vivo, we propose an operational 
strategy whereby exemplar molecules of 
known bias and efficacy (that have been 
quantified using in vitro methods) are tested 
in vivo to try to link in vitro estimates of 
agonist bias to phenotype profiles that are 
observed in vivo. Agonist bias can be deter-
mined63 using a mathematical formalism 
(termed Ba) that describes biased agonist 
signalling probabilities for tissues with a 
varying range of sensitivities; REF. 63 high-
lights the variability between in vitro and 
in vivo comparisons of bias. 
The impact of bias on drug discovery
Ligand-specific stabilization of seven-
transmembrane receptor conformation has 
influenced drug discovery in two major 
areas. First, because biased agonists do not 
produce monotonic stimulus–response cou-
pling, agonist potency ratios determined in 
whole cells can be shown to be dependent 
on the cell type and assay type (FIG. 6). Once 
the stimulus progresses beyond the allosteric 
vector and interacts with elements of the 
cytosol (such as ERK1 or ERK2 phosphoryl-
ation and calcium release from intracellular 
stores), then the cell controls the relative 
contributions from the various pathways 
to the overall cellular response. This means 
that different agonists may stabilize different 
conformations of a seven-transmembrane 
receptor to differentially interact with cell-
dependent pools of signalling proteins.
This, in turn, predicts that biased ago-
nists will have variations in relative potency 
ratios in different cell types and in different 
assay formats. This has been shown with the 
expression of calcitonin receptor agonists in 
different host cells64 or with the co-expression 
of different levels of G proteins in the same 
cell line65, and has also been observed when 
whole-cell agonist potency ratios are deter-
mined using different assay formats66. Such 
data suggest that whole-cell agonist potency 
ratios, at least for biased agonists, should be 
considered suspect as predictors of relative 
activity in other systems. Conversely, because 
biased agonists will probably produce vari-
ations in whole-cell potency ratios that are 
dependent on the assay format and cell type, 
the screening of agonists in different cells 
using label-free technology could provide  
a useful and rapid method of detecting 
biased agonists66. However, efficacy  
with in the allosteric vector will be cell  
type-independent (see Supplementary  
information S6 (box)).
Second, biased agonism may also  
control the quality of the efficacy in 
seven-transmembrane receptor signalling. 
Specifically, agonists acting on pleiotropically 
coupled receptors have the potential to cause 
bias towards some signalling pathways and 
not others; this, in turn, will affect the overall 
make-up of the signal passed on to the tissue. 
For example, parathyroid hormone activates 
G proteins and causes the receptor to asso-
ciate with β-arrestin, whereas analogues of 
the hormone can separate these pathways. 
The parathyroid hormone-related protein 
(PTHRP) analogue [Trp1]PTHRP-(1–36) 
causes the receptor to preferentially couple to 
G proteins, whereas PTH-1A ([d-Trp12,Tyr34]
PTH-(7–34)) causes the receptor to pref-
erentially couple to β-arrestin67. Similarly, 
the Substance P analogue SpD ([d-Arg1,d-
Phe5,d-Trp7,9,Leu11]Substance P) selectively 
induces G protein-dependent signalling, 
whereas bombesin induces G protein-
independent β-arrestin activity68. This type 
of selectivity imposes a further requirement 
on target validation in drug discovery: that is, 
determining which aspect of target signalling 
is therapeutically relevant.
In order to optimally predict the therapeu-
tic effects of biased agonists, it is necessary to 
determine the effects of the various agonists 
on different signalling pathways. This can  
be done by carrying out sequential screening 
Figure 6 | The interaction of the receptor and allosteric vector with cellular signalling components. 
The stabilization of unique receptor conformations (leading to biased signalling) is determined by 
the molecular properties of the agonist, receptor and signalling proteins (in this case the differ nt 
G proteins G
1
, G
2
, G
3
 and β-arrestin) at the level of the ternary complex; this is defined as the allosteric 
vector and shown in the orange rectangle. The strength of the signal imparted to the cell by the 
agonist is determined by the molecular parameters governing the direct activation of the receptor 
(efficacy, τ) and the allosteric effect of the ligand on endogenous receptor affinity (and efficacy 
(α and β, respectively, in the model described in Supplementary information S3 (box)). However, this 
signal can then interact with other pathways in the cell and the total cellular response thus becomes 
the result of an amalgam of stimuli. Under these latter circumstances, the relative stoichiometry 
of the signalling components in the cell can change the nature of the ultimate cellular response, 
making whole-cell responses cell type-dependent. AC, adenylyl cyclase; DAG, diacyl glycerol; ERK1, 
extra cellular signal-regulated kinase 1; Ins(1,4,5)P
3
, inositol-1,4,5-trisphosphate; MEK1, MAPK 
(mitogen-activated protein kinase)/ERK kinase 1; PAP, poly(A) polymerase; PKA, protein kinase A; 
PLCβ, phospholipase Cβ.
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of molecules in different assays (FIG. 7).  
Once exemplar molecules (that is, molecules 
that are biased for various pathways) have 
been identified, they can be tested in more 
complex models (for example, whole animal 
models of disease) to determine activity 
phenotypes that may allow more accurate 
predictions of therapeutic value. In addition, 
therapeutic linkages of bias profiles have 
been made using gene knockout animals  
(for example, knockout animals for 
β-arrestin 1 (REF. 69), β-arrestin 2  
(REF. 7) and p90 ribosomal S6 kinase48). 
Quantification of the bias observed  
with these exemplar molecules should  
then become a crucial part of the lead  
optimization phase of the drug discovery 
process.
Allosteric ligands and biased signalling
It is now well established that seven-
transmembrane receptors can possess 
allosteric binding sites that are recognized by 
small molecules, peptides or proteins70–74. 
Allosteric ligands promote distinct confor-
mational states that modulate the interactive 
properties of the receptor towards other 
ligands and/or intracellular signalling  
proteins75,76. In addition, there are several 
examples of allosteric ligands that can 
directly alter the basal signalling state of the 
receptor, thus acting as allosteric agonists.
There are also examples of direct  
allosteric agonists that promote a different 
signalling profile at a given receptor com-
pared to the cognate orthosteric agonist77–79. 
For example, in addition to allosterically 
potentiating the function of the orthosteric 
agonist R-PIA at the adenosine A1 receptor, 
the 2-amino-3-benzylthiophene VCP520 
activates the receptor in its own right to 
initiate signalling pathways that are differ-
ent from those activated by the orthosteric 
agonist79 (FIG. 8a). Another example is the 
allosteric tetrapeptide ASLW (Ala-Ser-Leu-
Trp), which promotes substantial activation 
of CXC chemokine receptor 4 (CXCR4) 
without inducing internalization, whereas the 
cognate agonist chemokine CXC ligand 12 
(CXCL12) mediates both processes78.
When investigating the effects of  
allosteric modulators in drug screening  
programmes, the interaction of the endo-
genous agonist must be considered, as  
endogenous agonists bind to sites that are 
separate from the allosteric modulator.  
Under these circumstances, allosteric 
modulators have the potential to change 
the coupling preferences of any co-bound 
Figure 7 | The impact of signalling bias on drug screening. a | Historically, it was assumed that all 
agonists lead to the formation of an identical receptor active state. Under this assumption, screening 
of a set of agonists (each represented by blue circles) selected the most active molecules in a given 
assay: for example, cyclic AMP accumulation. These molecules were then tested in secondary models. 
b | Now that it is known that biased agonism exists (that is, efficacy has a quality as well as magnitude), 
a larger sample of active molecules (encompassed by the red rectangle) from the first screen can be 
tested in an assay for another signalling pathway (for example, β-arrestin) to determine the relative 
activity of exemplar molecules (grey and red circles) on the two pathways. Under these circumstances, 
several molecules with differing biases can be tested in the model to determine possibly different 
phenotypes of activity in vivo.
Glossary
[35S]GTPγS
35S-labelled GTP; a non-hydrolysable G protein-activating 
analogue of GTP that is used to measure interactions 
between seven-transmembrane receptors (also known  
as GPCRs) and G proteins.
Allosteric binding site
The site on a seven-transmembrane receptor protein  
(also known as GPCR) to which modulators bind to affect 
the subsequent binding and effect of another ligand  
that interacts with the receptor; this ligand is usually  
the endogenous agonist binding to its cognate (that is, 
orthosteric) binding site.
Conditional affinity
The measured affinity of a ligand for a seven-transmembrane 
receptor (also known as GPCR) when the receptor is bound  
to an allosteric guest molecule (such as a G protein or 
β-arrestin). The conditional affinity of the ligand for the 
receptor will vary with the concentration and type of  
the guest molecule that is co-bound.
Efficacy
The property of a molecule that causes a change in the 
behaviour of a seven-transmembrane receptor (also known 
as GPCR) towards the cell when the molecule is bound to 
the receptor.
EC50
The concentration of an agonist that produces 50%  
of the maximal response to the agonist for a defined 
signalling response pathway.
Full agonists
Agonists that induce the maximum obtainable response 
that can be produced by a signalling system.
Operational affinity
Also referred to as functional affinity. The apparent 
equilibrium dissociation constant of the agonist–receptor 
complex, as determined by fitting the Black–Leff 
operational model to agonist concentration–response 
curves.
Orthosteric agonist
An agonist that binds to the same binding site on the  
seven-transmembrane receptor protein (also known  
as GPCR) as the endogenous agonist (that is, the 
orthosteric binding site). 
pEC50
Negative logarithm of the EC50 (the concentration  
of an agonist that produces 50% of the maximal  
response to the agonist for a defined signalling  
response pathway).
Receptor coupling efficiencies
A term that describes the degree of seven-transmem-
brane receptor (also known as GPCR) occupancy by an 
agonist; receptor coupling efficiency relates to the 
resulting cellular response. A low receptor occupancy  
that yields a large cellular response constitutes a high 
coupling efficiency.
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orthosteric endogenous agonists, leading  
to the phenomena of biased antagonism  
or potentiation. This has been shown for 
prostaglandin D2 receptor 2 (PTGDR2;  
also known as CRTH2)80, metabotropic glu-
tamate receptors81, neurokinin 2 (also known 
as substance K) receptors82, musca rinic M1 
(REF. 83) and M3 receptors
84, prostaglandin F2α 
receptors85 and the calcium-sensing recep-
tor86. For example, when acting on PTGDR2 
the allosteric modulator 1-(4-ethoxyphenyl)-
5-methoxy-2-methylindole-3-carboxylic 
acid acts as an antagonist of G protein-
independent β-arrestin coupling promoted 
by prostaglandin D2, but has no effect on  
G protein-mediated signalling80.
FIGURE 8b summarizes the effects of the 
allosteric modulator LY2033298 on the  
ability of several orthosteric agonists to 
mediate the binding of [35S]GTPγS to acti-
vated G proteins or the phosphorylation of 
ERK1 or ERK2 via the M2 receptor. Despite 
being a partial allosteric agonist when acting 
on its own at the M2 receptor, LY2033298 
can dramatically modify the signalling pro-
file of the M2 receptor when the receptor is 
co-bound with an orthosteric agonist such 
as acetylcholine. For example, although 
acetylcholine-mediated ERK1 or ERK2 
phosphorylation is essentially unaltered, 
acetylcholine-mediated [35S]GTPγS binding 
is potentiated when LY2033298 is present, 
and LY2033298 completely abrogates the 
signalling of the agonist xanomeline at both 
pathways83; the modulator essentially con-
verts xanomeline from an agonist into an 
antagonist (FIG. 8b).
Findings such as these have substantial 
implications for modern preclinical drug 
discovery. In addition to highlighting the 
need to profile the activity of candidate  
compounds as broadly as possible, these 
findings have significance when screening  
for allosteric modulators: namely, the char-
acteristics of the orthosteric agonist that 
is used as a reference probe for measuring 
seven-transmembrane receptor activity and 
modulation should be carefully considered. 
Ideally, the endogenous agonist should be 
used; if a different agonist is used (to the 
endogenous one), this can result in types of 
modulation and bias that are not seen with 
(and thus not predictive of the effects on)  
the endogenous agonist. If a given receptor 
has more than one endogenous agonist,  
then all of these agonists should be tested87.
A third and relatively unappreciated 
consideration is the fact that the signalling 
produced by metabolites of endogenous ago-
nists may also be prone to allosteric modula-
tion in a manner that is different from the 
parent molecule. For example, the signalling 
properties of the metabolic products choline, 
inosine and GLP1 (glucagon-like peptide 1; 
residues 9–36) undergo substantial allosteric 
modulation by chemically distinct allosteric 
ligands of the M2, A1 adenosine and GLP1 
receptor, respectively88. This finding high-
lights that the bias induced by several endog-
enous agonists and their metabolic products 
has an impact on both physiology and in 
disease, and must therefore be considered 
when assessing biased signalling.
Therapeutic implications
Although several biased agonists have 
been described from in vitro profiles in the 
literature, the therapeutic impact of this 
phenomenon in vivo is still not clear. Some 
predictions have been made suggesting that 
the pharmacological activation of some — 
but not all — of the signalling produced 
by agonists is beneficial to the host organ. 
For example, although opioids are useful 
analgesics, they can also produce respira-
tory depression — an effect that is linked to 
the activation of β-arrestin7. Therefore, an 
Figure 8 | Biased allosteric agonism and modulation. a | The bias plot 
shows the signalling preferences of the allosteric agonist VCP520 and 
orthosteric agonist R-PIA for the inhibition of forskolin-stimulated cyclic 
AMP or stimulation of extracellular signal-regulated kinase 1 (ERK1) or 
ERK2 phosphorylation via the adenosine A
1
 receptor. Data modified, with 
permission, from REF. 79 © (2012) American Chemical Society. b | The allos-
teric modulator LY2033298 changes the signalling properties of the M
2
 
muscarinic receptor in an orthosteric ligand (xanomeline)- and pathway-
dependent manner. The left panel shows the effect of LY2033298 on the 
concentration–response relationship produced by the orthosteric agonist 
xanomeline on ERK1 or ERK2 phosphorylation. The right panel shows 
the cooperativity estimates (αβ values as measures of the overall degree 
of allosteric potentiation or inhibition) for the interaction between 
LY2033298 and the indicated orthosteric agonist across two different 
pathways: [35S]GTPγS binding or ERK1 or ERK2 phosphorylation. Data 
modified, with permission from REF. 115 © (2012) American Society for 
Pharmacology and Experimental Therapeutics. ACh, acetylcholine; 
pERK, phosphorylated ERK. 
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opioid agonist that stimulates opioid analge-
sia pathways without promoting receptor–
β-arrestin interactions would be predicted to 
have fewer side effects8–10.
It should also be noted that the occu-
pancy of receptors by biased ligands may 
preclude receptor occupancy by the endoge-
nous agonists, and this may be an important 
feature of the therapeutic profile of biased 
ligands. For example, blockade of angio-
tensin receptors with standard angiotensin-
blocking drugs such as losartan precludes 
the damaging angiotensin-mediated vaso-
constriction in heart failure. In vivo treat-
ment with a biased angiotensin ligand such 
as TRV120027 (Sar-Arg-Val-Tyr-Ile-His-
Pro-d-Ala-OH) blocks angiotensin but also 
promotes the beneficial effects of β-arrestin 
activation (via stimulation of p42 and/or p44 
MAPK, SRC and endothelial nitric oxide 
synthase phosphorylation) and is thus pre-
dicted to have a therapeutic advantage89–93.
In vivo data to support this come from 
studies using rats in which blockade of 
endogenous angiotensin with the conven-
tional angiotensin receptor antagonists 
losartan or telmisartan led to reduced mean 
arterial pressure as well as a decrease in 
cardiac performance. However, rather than 
decreasing cardiac performance, treatment 
with the biased ligand TRV120027 increases 
cardiac performance and preserves cardiac 
stroke volume94. A similar effect is seen 
in canine models of heart failure in which 
TRV120027 produces cardiac unloading 
actions but preserves renal function95,96.
At present, biased signalling is proposed to 
be useful in several diseases, including heart 
failure (β-adrenergic receptors)97–99, hyper-
lipidaemia (nicotinic acid receptors)100,101,  
hypertension (α2-adrenergic receptors)
102, 
some neuropsychiatric and/or neurodegen-
erative disorders (histamine H1 receptors)
103, 
hypothyroidism (thyroid-stimulating hor-
mone receptor)104, small-cell lung cancer 
(gastrin-releasing peptide (GRP) and vaso-
pressin receptors)68, schizophrenia (dopa-
mine D2 receptors)
105–107, osteoporosis (PTH 
receptors)67,108,109, Parkinson’s disease (dopa-
mine D1 receptors)
110, diabetes (GLP1  
receptors)69, as well as addiction, psychosis  
and depression (5-hydroxytryptamine 
(5-HT; serotonin) receptors)111–113.
It should also be noted, however, that 
there is no a priori reason to expect ligand 
bias to be associated only with improved 
therapeutic outcomes. It is possible that 
biased signalling may also be associated with 
undesirable side effects and even contribute 
to disease. Recent findings provide support 
for the possibility that biased signalling could 
have detrimental effects. For example, the 
bacterium Neisseria meningitidis possesses 
filamentous structures known as pili and 
these have been shown to interact in a biased 
and allosteric manner with the β2-adrenergic 
receptor to initiate signalling cascades that 
facilitate meningeal colonization114.
Conclusions
The ability of seven-transmembrane recep-
tors to form different ligand-induced con-
formations necessitates a specific analysis of 
the consequences of ligand-induced activa-
tion of these receptors, either in the form 
of the direct signalling induced or via the 
changes induced in the direct signalling of 
their endogenous agonists. In our view, the 
data to date that we have highlighted above 
indicate that the most reliable methods for 
characterizing the ability of new ligands to 
produce these effects include the quantifica-
tion of ligand bias ratios determined from 
transduction coefficients (ΔΔlog(τ/KA)) 
and/or in some cases relative activity values 
(ΔΔlog(RA)).
At present, however, these tools only allow 
the characterization of molecules that then 
need to be tested in vivo to further assess the 
impact of biased signalling on therapeutic 
responses. The therapeutic promise of biased 
signalling augurs that a wave of biased ligands 
are poised to enter the clinic. At present, the 
most advanced molecule is the biased angio-
tensin ligand TRV120027 (REFS 95,96). It will 
be interesting to see the therapeutic phenotypic 
profile of this and other biased molecules in 
future drug therapy.
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